$NBIO April 12, 2022 / Nascent Biotech, developer
Post# of 72715
(Total Views: 143)
Posted On: 04/12/2022 11:29:22 AM
$NBIO April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure (HOS).
Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification. https://www.otcmarkets.com/stock/NBIO/news/Na...?id=351972
Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification. https://www.otcmarkets.com/stock/NBIO/news/Na...?id=351972
(0)
(0)Scroll down for more posts ▼